GSK PLC-SPON ADR (GSK) Institutional Ownership Changes & 13F Activity

GSK PLC-SPON ADR (GSK) institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC 13F filings (Q1 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions among tracked filers. Notable filers include Dodge & Cox Stock Fund, Renaissance Technologies LLC, Causeway Capital Management, Kahn Brothers Group, and Hillman Value Fund.

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q1 2026Dodge & Cox Stock FundSell-9,854,99558,662,974$3,237,609,535
Q1 2026Renaissance Technologies LLCSell-724,280311,292$17,180,205
Q1 2026Causeway Capital ManagementSell-22,78711,110$613,177
Q1 2026Kahn Brothers GroupSell-17,714160,982$8,884,596
Q1 2026Hillman Value FundSell-16,90497,432$5,377,272
Q1 2026Hancock Classic ValueBuy5,37918,823$1,038,836
Q1 2026Sequoia Financial AdvisorsBuy1,84735,652$1,967,623
Q1 2026Tweedy, Browne Co All Funds (US)Sell-45881,785$4,513,714
Q4 2025Dodge & Cox Stock FundSell-9,885,76568,517,969$3,360,121,200
Q4 2025Causeway Capital ManagementSell-1,143,10433,897$1,662,321
Q4 2025Renaissance Technologies LLCSell-952,3811,035,572$50,784,451
Q4 2025Kahn Brothers GroupSell-82,141178,696$8,763,251
Q4 2025Hillman Value FundSell-27,443114,336$5,607,037
Q4 2025Hancock Classic ValueBuy4,72713,444$659,292
Q4 2025Sequoia Financial AdvisorsBuy1,13133,805$1,657,803
Q3 2025Kahn Brothers GroupSell-399,035260,837$11,257,724
Q3 2025Dodge & Cox Stock FundSell-354,13578,403,734$3,383,905,159
Q3 2025Renaissance Technologies LLCSell-262,9001,987,953$85,800,051
Q3 2025Causeway Capital ManagementBuy69,9251,177,001$50,799,344
Q3 2025Hillman Value FundSell-10,820141,779$6,119,182
Q3 2025Sequoia Financial AdvisorsBuy5,92932,674$1,410,214
Q3 2025Tweedy, Browne Co All Funds (US)Sell-4,62882,243$3,549,608
Q3 2025Hancock Classic ValueBuy1,2078,717$376,237
Q2 2025Kahn Brothers GroupBuy659,872659,872$25,339,084
Q2 2025Renaissance Technologies LLCBuy268,7002,250,853$86,432,755
Q2 2025Dodge & Cox Stock FundBuy106,03678,757,869$3,024,302,170
Q2 2025Hillman Value FundSell-12,544152,599$5,859,802
Q2 2025Hancock Classic ValueBuy7,5107,510$288,384
Q2 2025Tweedy, Browne Co All Funds (US)Sell-3,67486,871$3,335,846
Q2 2025Sequoia Financial AdvisorsBuy3,45126,745$1,027,028

Frequently asked questions about GSK activity

  • Which institutional owners are buying GSK?

    Institutional owners buying GSK include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in GSK activity?

    "Buy" means an investor increased their reported position in GSK compared to the prior reporting period. This reflects growing exposure to GSK PLC-SPON ADR (GSK) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in GSK increasing?

    Institutional interest in GSK can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.

Related GSK insights